Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Juvenile Idiopathic Arthritis – Long-term Safety and Efficacy
CTR20181492Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (SJIA), juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), sponsored by Pfizer. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)systemic juvenile idiopathic arthritis (SJIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on CTR20181492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181492.